Cargando…
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analy...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361083/ https://www.ncbi.nlm.nih.gov/pubmed/16404366 http://dx.doi.org/10.1038/sj.bjc.6602924 |
_version_ | 1782153137193222144 |
---|---|
author | Went, P Vasei, M Bubendorf, L Terracciano, L Tornillo, L Riede, U Kononen, J Simon, R Sauter, G Baeuerle, P A |
author_facet | Went, P Vasei, M Bubendorf, L Terracciano, L Tornillo, L Riede, U Kononen, J Simon, R Sauter, G Baeuerle, P A |
author_sort | Went, P |
collection | PubMed |
description | Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P<0.0001). Adenosquamous and squamous carcinomas of the lung had a lower percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and 17.3% of tumours being Ep-CAM negative. With the exception of moderately differentiated colon carcinoma, where patients not expressing Ep-CAM on their tumours showed an inferior survival (P=0.0014), correlation of Ep-CAM expression with survival did not reach statistical significance for any of the other cancer indications and subgroups. In conclusion, the data strongly support the notion that Ep-CAM is a prime target for immunotherapies in major human malignancies. This is because the most common human cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression. |
format | Text |
id | pubmed-2361083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23610832009-09-10 Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers Went, P Vasei, M Bubendorf, L Terracciano, L Tornillo, L Riede, U Kononen, J Simon, R Sauter, G Baeuerle, P A Br J Cancer Molecular Diagnostics Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287). No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers. The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P<0.0001). Adenosquamous and squamous carcinomas of the lung had a lower percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and 17.3% of tumours being Ep-CAM negative. With the exception of moderately differentiated colon carcinoma, where patients not expressing Ep-CAM on their tumours showed an inferior survival (P=0.0014), correlation of Ep-CAM expression with survival did not reach statistical significance for any of the other cancer indications and subgroups. In conclusion, the data strongly support the notion that Ep-CAM is a prime target for immunotherapies in major human malignancies. This is because the most common human cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression. Nature Publishing Group 2006-01-16 2006-01-10 /pmc/articles/PMC2361083/ /pubmed/16404366 http://dx.doi.org/10.1038/sj.bjc.6602924 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Went, P Vasei, M Bubendorf, L Terracciano, L Tornillo, L Riede, U Kononen, J Simon, R Sauter, G Baeuerle, P A Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title | Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title_full | Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title_fullStr | Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title_full_unstemmed | Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title_short | Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers |
title_sort | frequent high-level expression of the immunotherapeutic target ep-cam in colon, stomach, prostate and lung cancers |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361083/ https://www.ncbi.nlm.nih.gov/pubmed/16404366 http://dx.doi.org/10.1038/sj.bjc.6602924 |
work_keys_str_mv | AT wentp frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT vaseim frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT bubendorfl frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT terraccianol frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT tornillol frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT riedeu frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT kononenj frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT simonr frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT sauterg frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers AT baeuerlepa frequenthighlevelexpressionoftheimmunotherapeutictargetepcamincolonstomachprostateandlungcancers |